BioStem's hospital-focused strategy delivered a 39% gross margin in Q2, up from 30%. Cash runway extends through year-end. A 510(k) submission for a new surgical graft is expected before Q3 closes.
Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality, moderate sentiment.
BioStem Technologies posted $2 million in second-quarter revenue, its first full quarter operating as a hospital-focused business. The company swung to a net loss of $1.5 million, or 4 cents a share, from a year-earlier profit of $1.1 million, driven by a $1.5 million non-cash expense tied to warrant revaluation and higher operating costs.
Gross margin came in at 39%, up from 30% a year earlier, as the shift to direct hospital sales cut out distributor margins. The gross profit of $780,000 covered operating expenses of $2.3 million, leaving an operating loss of $1.5 million.
Cash and equivalents stood at $2.8 million at quarter-end, down from $4.2 million at the start of the year. The company does not expect to need outside financing before the end of 2026, CEO Jason Matuszewski said on the earnings call.
Revenue from the hospital channel rose to $1.7 million, or 85% of total sales. The company's wound-care products, including its AmnioFill and AmnioWrap grafts, are now used in 45 hospital systems, up from 28 at the end of 2025. Matuszewski said the company added seven new accounts in the quarter.
The commercial team has grown to 28 representatives, and the company plans to add another six to eight by year-end, Barry Hassett, chief commercial officer, said. The sales cycle for hospital accounts runs 9 to 12 months, he said, meaning the second-half pipeline should benefit from accounts opened in the first half.
On the product side, BioStem is preparing a 510(k) submission for a new dehydrated amniotic membrane product for surgical applications. Matuszewski said the filing is expected before the end of the third quarter. The company's clinical study for its diabetic foot ulcer product is enrolling patients, with data expected in the first half of 2027.
Selling, general and administrative expenses rose to $1.8 million from $1.5 million a year ago, reflecting the expanded sales force. Research and development spending was $460,000, up from $340,000.
The stock closed at $1.60, down 3%. The company has a market capitalization of roughly $60 million.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.